Purpose: Approximately 25-30% of breast and ovarian carcinomas have amplification of the HER-2/neu Oncogene.
The present study focuses o n the exploration o f HER-21neu amplification in breast cancer using FISH as an alternative or adjunct to the traditional methodologies o f immunohistochemistry (IHC) and molecular biology. We aim to establish whether HER-21neu amplification as detected b y FISH characterizes a subset o f breast cancer, and whether this is correlated with the clinical stage o f the disease. paraffin-embedded tissue blocks of the cases were retrieved from the routine surgical pathology files of the Department of Pathology. For each specimen, 6-micron thick consecutive sections were cut. At least one slide from consecutive sections was stained by H & E, the diagnosis confirmed and the location of the tumor cells identified. The tumors were also evaluated for histological grade according to a modified Bloom and Richardson grading s y~t e m ,~ although we did not segregate the tumor specimens in the present study according to pathologic grade. The sections adjacent to the H & E stained section were then processed for FISH. FISH assays were performed and HER-2lneu and CEP 17 signals were enumerated in the target areas where tumor cells were located. Extra sections, wherever available, were prepared for possible repeat of the assay.
MATERIALS AND MmHODS

Breast cancer cases
Fluorescent in situ hybridization
For fluorescent in situ hybridization (FISH),6-8 manufacturer's instructions (Vysis, Downers Grove, IL) were followed. Briefly, formalin-fixed, paraffin-embedded, 6-micron thick tissue sections were applied to silanized glass slides. Slides were baked at 60°C for 60 minutes. Specimens were deparaffinized by immersing them three times in Histoclear (National Diagnostics, Atlanta, GA) for at least 10 minutes each at room temperature, dehydrated, and air-dried. Slides were pretreated by immersing in 0.2 N HCl for 20 minutes, washed and treated with a Pretreatment Solution composed of 1 N sodium thiocyanate (NaSCN) at 80°C for 30 minutes. After washing with distilled water and a Wash Buffer (2XSSC, pH 7.4), the slides were treated for 10 minutes at 37°C in a Protease Solution (2500-3000 Ulmg Protease, lyophilized, 0.9% NaCl, pH 2.0). The slides were subsequently washed twice in Wash Buffer for 5 minutes, and air-dried. They were then placed in 10% buffered formalin at room temperature for 10 minutes, washed twice in Wash Buffer for 5 minutes and air-dried. Thereafter, the protocol for FISH on regularly prepared cytogenetic slides were followed.
Specimen slides were denatured in 70°/o formamidel2 x SSC (pH 7.0-8.0) at 72°C and immediately washed in 70%, 85%, and 100% ethanol rinses. Ten microliters of the pre-mixed, pre-denatured HER-21neu probe was applied to the target area on each slide. A 22 mm X 22 mm glass coverslip was applied to the slide. The coverslip was sealed with rubber cement. Slides were then incubated overnight in a 37°C incubator.
The Vysis (Downers Grove, IL) LSI HER-21neu DNA probe is a Spectrumorange directly labeled fluorescent DNA probe specific for the HER-2Ineu gene locus (17q11.2-q12). The CEP 17 DNA probe is a SpectrumGreen directly labeled fluorescent DNA probe specific for the a-satellite DNA sequences at the centromeric region of chromosome 17 ( 17p 1 1.1-ql i . i ).
Fluorescent signal scoring
Hybridization signals were enumerated among tumor cells. The target areas were identified by H & E stain on every tenth slide of the same tissue block. As a quality control measure a reproducibility study (data not shown) was performed to ensure repeatability of results and reliability of data, details of which will be described elsewhere (Masood et al., unpublished data) . Once the quality control/quality assurance nieasures have been satisfied, scoring was performed under 1000X magnification independently by operators without any prior clinical information or knowledge of other histological and pathological results. A standardized signal enumeration guide was followed, in which non-overlapping nuclei with well-defined nuclear outlines were chosen for scoring fluorescent signals, as adopted by Mark et dl.,'-l4 Kim et al., I5 and Hopman et al.' " Only bright, unambiguous signals were scored as positive. Slides with suboptimal quality hybridizations were repeated and reanalyzed. Because the nuclei are usually present in slightly different planes of the section, the focus of the microscope was constantly adjusted to enable all positive signals to be visualized. Except for one tumor with 42 scorable cells and one case with 46 scorable cells, all other 38 tumors had 99-133 evaluable cells for FISH analysis.
Calculation of amplification ratios
The raw data on the number of HER-2lneu gene copy number and CEP 17 copy number were entered in a 2-way table. The average copy numbers for both HER-2lneu and CEP 17 were calculated separately using the marginal totals in the 2-way table. For example, if for HER-2/neu, there were 10 cells with 5 copies, 10 with 7 copies, 5 with 11-1 5 copies, and 5 cells with 2 0 copies in a sample of 30 cells, the average copy number would be calculated as follows:
HER-2/neu copy number = [10 X 5 + 10 X 7 $5 X 13' + The amplification ratio is then calculated by dividing the HER-2Ineu copy number by the CEP copy number to correct for copy number. For example, for the above illustration, if the CEP 17 copy number were found to be 2, then the amplification ratio would be 10.33 divided by 2 or 5.165.
Slides with amplification ratios of less than 1.5 were classified as "nonamplified." Slides with amplification ratios equal to or greater than 1.5 were classified as "amplified." Furthermore, ratios between 1.5 and 2.0 were considered as "low amplification." Ratios between 2.1 and 4.0 were considered as "moderate amplification." Ratios exceeding 4.0 were considered as "high amplification." An analogous classification system was used by Young et al. (1996) I7in ovarian cancer, although the protocols for amplification ratio calculations in our two studies are not completely equivalent.
RESULTS
A total of 40 specimens of formalin-fixed, paraffin-embedded breast cancer tissues were analyzed cytogenetically, in a blinded fashion, for HER-21neu gene amplification using a previously optimized FISH protocol (Masood et al., 1998) .lX The results of the present FISH study are given in Table 1 . Of the 40 cases studied, 10 were stage I, 10 were stage II,10 were stage 111, and 10 were stage IV.
Using the criteria defined above, the frequency of HER-Zlneu gene amplification among stage I tumors was 30% (3 out of 10). Of these, one-third (1 out of 3) showed low amplification, onethird (1 out of 3) were moderately amplified, and one-third (1 out of 3) were highly amplified. The frequency of HER-2Ineu gene amplification anlong stage I1 tumors was 0% (0 out of 10). The frequency of HER-2lneu gene amplification among stage I11 tumors was 10% (1 out of 10). The sole tumor found positive was classified as moderately amplified by our criteria. The frequency of HER-2Ineu gene amplification among stage IV tumors was 50% (5 out of 10). Four of the 5 tumors found positive were highly amplified. These results are summarized in Table 2 . Representative fields illustrating HER-2Ineu non-amplification and gene amplification are given in Figures 2 and 3 . 
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DISCUSSION
The HER-2/neu oncogene codes for a 185 kilodalton transmembrane oncoprotein. Approximately 25-30% of breast and ovarian carcinomas have amplification of the HER-2/neu gene.'9-2' Gene amplification is a characteristic of cancer cells that allows increased production of specific proteins used for the acquisition and maintenance of the malignant phenotype. Amplification of oncogenes may play important roles in the progression of many tumors. FISH is a useful technique for quantitation of HER-2/neu gene amplification because it can assess the level of HER-2/neu gene amplification directly in the tumor cells while retaining the characteristic morphology of the tissue studied. FISH assay is rapid, non-radioactive, requires very little material, and is capable of detecting lower level amplification (2-8 gene copies) of the oncogene. Preliminary data indicate that FISH is probably superior to Southern blot or immunohistochemistry analysis (Vysis, unpublished data). In a recent study, Persons, Borelli, and HsuZ2 found that the immunoperoxidase procedure was less reproducible than FISH in touch preparations from pulverized tumors. They postulated that several factors most likely contributed to their findings. First, the increased reproducibility of FISH might be related to the objectivity associated with FISH analysis (i.e., counting fluorescent signals) compared with the subjectivity involved with analyzing immunoperoxidase stained cells or tissue (i.e., visually estimating the degree of intensity of staining and percentage of nuclei stained). A second factor that might contribute to the discrepancies between the two procedures may be the relative stability of DNA compared \vith protein, especially in paraffin-embedded samples.
FISH may also overcome many of the inherent technical limitations and difficulties in interpretation associated with other techniques. In the present study, FISH assessment of HER-2/neu amplification was achieved with the LSI HER-2/neu Orange and CEP 17 Green DNA dual color probe. Fluorescent signals in interphase nuclei on formalin-fixed paraffin-embedded archival slides were enumerated. The use of chromosome 17 copy number to derive the amplification ratio served as an internal control to distinguish between polysomy chromoson~e 17 and oncogene amplification.
As can he seen by examining the data presented in Tables 1  and 7 , the overall frequency of gene amplification was 22.5%. This is comparable to the 25-30% frequency generally quoted in the literature for breast and ovarian cancers."-"
From Table 1 , it can he seen that 1 out of 3 tumors showed low amplification, 1 out of 3 showed moderate amplification, and 1 out of 3 showed high amplification in Stage I disease. The overall frequency of HER-2/neu gene amplification among stage I tumors was 30% (3 out of 10 tumors studied). The overall frequency of HER-Zlneu gene amplification among stage 11 tumors was 0% (0 out of 10 tumors studied). Among stage I11 tumors, the one positive tumor was moderately amplified. The overall frequency of HER-2lneu gene amplification among stage 111 tumors was 10% ( 1 out of 10 tumors studied). The highest frequency of HER-2/neu gene amplification occurred in stage IV disease. Among 5 amplified tumors, 1 was moderately amplified and 4 were highly amplified by our criteria. The overall frequency of HER-2/neu gene amplification among stage IV tumors was 50% (5 out of 10 tumors studied).
No apparent linear relationship could be seen between HER-2/neu gene amplification frequency and clinical stage of the disease in this pilot sample. However, when the data are examined as to the levels of gene amplification (low, moderate, or high amplification) as defined, it can be seen not only that the stage I V tumors had the highest frequency of HER-2/neu gene amplification, but also that 4 out of 5 amplified tumors were highly amplified.
Although a correlation between the overall frequency of HER-2/neu amplification and clinical stage cannot be established at this time because of the size of this sample, it is interesting to note that when stages I and 11, and when stages I11 and IV are combined, respectively, the higher tumor stages have a higher amplification frequency than the lower ones. The combined frequency of amplification in stages 111 and IV tumors was 30% (6 out of 20 tumors studied) versus 15% ( 3 out of 20 tumors studied) for stages I and I1 tumors. Furthermore, stage IV has the highest frequency (5 out of 10) of HER-2/neu gene amplification than all three lower stages combined (4 out of 30). This is no doubt due to the high frequency of gene amplification observed Recent studies showed that an overexpression or amplification of HER-2/neu in breast tumor tissue is associated with aggressive disease (Zhou et al., 1987) ,*~ disease recurrence (Press et al., 1993) ,20 poor overall survival (Slamon et al., 1987) ,19 and differential drug responsiveness (Muss et al., 1994) .24 However, these results were not consistently observed in the literature. Apart from disease stage, clinical information such as ERIPR positivity is not complete. Available information indicates that this cohort of patients ranged from 34 to 89 years of age, with means of 61, 60,65, and 65, for stages I, 11,111, and IV, respectively. The size of the tumors ranged from 0.6 cm to 4.5 cm, with the larger tumors found in the higher stages. Pathological grade ranged from Grades I to I11 in stages I, I1 To conclude, although the biologic and clinical basis for gene amplification is not totally clear at this time, given the observation that the most aggressive disease stage is associated with the highest frequency of gene amplification, further exploration of HER-21neu as a prognostic marker of poor outcome is warranted, as it may have significant clinical utility such as in selecting patients for adjuvant therapies (Slamon, 1987; Press, 1993) .I9v2O
